Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis
Clinical and Translational Allergy · 2025-08 · 15 (8)
DOI: 10.1002/clt2.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 08.08.2025. Verfasst von Christiane E Whetstone und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Canada.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Methods
After a 4‐week washout from oral anti‐inflammatory medications 20 patients with moderate to severe AD completed a randomized, double‐blind, placebo‐controlled parallel‐group study comparing 3 doses q4wk 30 mg subcutaneous benralizumab to placebo. Lesional and unaffected skin biopsies were collected before and after 28 and 65 days of treatment, respectively, for quantification of eosinophils and IL‐5Rα‐bearing cells in papillary dermis. Histological measurements of epidermal thickness, spongiosis, neutrophilic and lymphocytic infiltration, as well as clinical scores EASI, SCORAD, IGA, DLQI, and POEM were conducted throughout the study. Outcomes were compared between placebo and benralizumab treatment groups using a Mann‐Whitney U ‐test.
Results
Benralizumab, compared to placebo, reduced IL‐5Rα+ cells and MBP+ EG2+ eosinophils in lesions and unaffected skin ( p < 0.05). In skin lesions, benralizumab reduced MBP+ eosinophils and basophils but had no effect on eosinophil progenitor (EoP; CD34+ IL‐5Rα+) or mast cell numbers. There was no change in other skin histological measurements or IGA scoring of the observational lesion, nor improvement in clinical scores.
Conclusion
Benralizumab treatment significantly inhibited accumulation of MBP+ eosinophils and basophils in lesional skin of patients with moderate to severe AD. However, a lack of improvement in histological and clinical outcomes suggests that other inflammatory pathways are central to the pathobiology of severe atopic dermatitis. Trial Registration (ClincialTrials.gov number, NCT03563066)
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
- Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Division of Allergy and Immunology, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Gail M Gauvreau
Förderung
- AstraZeneca Canada
Zitieren
APA
Whetstone, C. E., Cusack, R. P., Price, E. L., Howie, K. J., Stevens, C., Al-Sajee, D., Beaudin, S., Wattie, J., Alsaji, N., Schlatman, A., Luk, V., O'Byrne, P. M., Inman, M. D., Sehmi, R., Lima, H., & Gauvreau, G. M. (2025). Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis. Clinical and Translational Allergy, 15(8). https://doi.org/10.1002/clt2.70090
Vancouver
Whetstone CE, Cusack RP, Price EL, Howie KJ, Stevens C, Al-Sajee D, et al. Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis. Clinical and Translational Allergy. 2025;15(8). doi:10.1002/clt2.70090
BibTeX
@article{Whetstone2025,
author = {Whetstone, Christiane E and Cusack, Ruth P and Price, Emma L and Howie, Karen J and Stevens, Caitlin and Al-Sajee, Dhuha and Beaudin, Suzanne and Wattie, Jennifer and Alsaji, Nadia and Schlatman, Abbey and Luk, Vanessa and O'Byrne, Paul M and Inman, Mark D and Sehmi, Roma and Lima, Hermenio and Gauvreau, Gail M},
title = {Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis},
journal = {Clinical and Translational Allergy},
year = {2025},
volume = {15},
number = {8},
doi = {10.1002/clt2.70090}
}
EUVIMED